InMed Pharmaceuticals Inc. (NASDAQ: INM) reported Q3 EPS of ($1.94), $1.94 worse than the analyst estimate of $0.00. Revenue for the quarter came in at $1.26 million versus the consensus estimate of $0 .

For earnings history and earnings-related data on InMed Pharmaceuticals Inc. (INM) click here.